Giant secreting adrenal myelolipoma in a man: a case report by Alfio Brogna et al.
CASE REPORT Open Access
Giant secreting adrenal myelolipoma in a man:
a case report
Alfio Brogna, Giuseppe Scalisi*, Rosario Ferrara and Anna M Bucceri
Abstract
Introduction: Adrenal myelolipoma is a rare, benign neoplasm that is usually asymptomatic, unilateral and
nonsecreting. It develops within the adrenal gland and is composed of mature adipose tissue with elements of the
hematopoietic series. We describe the case of what is, to the best of our knowledge, one of the largest secreting
adrenal myelolipomas reported in the literature.
Case presentation: A 52-year-old Caucasian man of medium build who had had moderate hypertension for three
years presented to our hospital. He had no other significant symptoms. His hypertension was pharmacologically
treated. He came to our hospital to undergo abdominal ultrasonography during a clinical checkup. The ultrasound
scan showed the presence of a voluminous hyperechoic mass interposed between the spleen and the left kidney.
It was reported as a myelolipoma of the left kidney on the basis of its structural characteristics and position.
Computed tomography confirmed our diagnosis. All preoperative biochemical tests were normal, with the
exception of high serum cortisol, which was being overproduced by the lesion and was probably responsible for
the patient’s hypertension. He underwent successful surgery, and his postoperative course was uneventful. The
pathologic examination of the lesion confirmed the diagnosis of adrenal myelolipoma. The patient’s blood pressure
returned to within the normal range.
Conclusions: The “incidental” discovery of an adrenal mass requires careful diagnostic study to plan adequate
therapeutic management. Both of the primary investigations at our disposal, ultrasound and blood tests (adrenal
hormones), helped in rendering the diagnosis and allowed us to move toward the most appropriate treatment,
taking into account the size of the tumor and its probable hormonal production.
Introduction
The myelolipoma is a rare, benign neoplasm composed
of mature adipocytes and hematopoietic tissue. It was
first described by Gierke in 1905 and subsequently by
Oberling in 1929, who used the term “myelolipoma” [1].
In the past, the finding of adrenal lesions was made pos-
sible by autopsy or by clinical presentation, related either
to the massive growth of the gland or to altered hormone
production. Today these tumors can be discovered inci-
dentally because of the wide use of diagnostic imaging
methods, such as ultrasonography (US), computed tomo-
graphy (CT) and magnetic resonance imaging [2].
Although the incidence of these tumors is unknown, it is
thought to be between 0.08% and 0.4%. Men and women
seem to be equally affected by these tumors. Adrenal
myelolipoma is most commonly found between the fifth
and seventh decades of life [3]. In the latter age group, its
low incidence seems to have increased by 0.2% to 10%
since the mid-1990s [4].
These lesions are usually unilateral and asymptomatic. A
certain number of bilateral tumors have been described in
the literature. Myelolipomas are often smaller than 4 cm
in diameter, although they can reach wider sizes [5]. The
largest adrenal myelolipoma reported in the literature
weighed 6 kg and measured 31 cm × 24.5 cm × 11.5 cm
[6,7]. After surgical excision, these lesions generally do not
recur. They are generally nonsecreting, although an over-
production of adrenal hormones is described in some
cases. More than 25 cases of endocrine dysfunction asso-
ciated with myelolipoma have been reported in the Eng-
lish- and Japanese-language literature [5,8,9]. Here we
describe one of the largest cortisol-secreting myelolipomas
ever reported in the literature [10,11].
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Case presentation
We report the case of a 52-year-old Caucasian man of
medium build who had had moderate hypertension for
three years. He referred to no other noticeable symptom.
His hypertension was pharmacologically treated. The
patient came to our hospital to undergo abdominal ultra-
sonography during a clinical checkup. US showed the
presence of a large hyperechoic mass (Figure 1) with
non-well-defined boundaries that made it difficult to
measure its exact size. It seemed to be 20 cm in diameter.
The mass was interposed between the spleen and the left
kidney. The left kidney was displaced downward. A prob-
able myelolipoma of the left adrenal gland was diagnosed.
Contrast-enhanced CT was proposed to confirm the
diagnosis. The abdominal CT scan confirmed the pre-
sence of an expansive lesion (Figure 2) largely occupying
the left hemiabdomen. Such a lesion rising from the left
adrenal gland had frankly fat content, with delta numbers
equal to a mean of -130 HU. It had sharp, regular bound-
aries with starlike central calcifications. It was suggestive
of a giant left adrenal myelolipoma. The spleen was
pushed against the costal wall and slightly displaced cra-
nially, while the left kidney was pushed downward and
the left renal artery and vein were stretched. The com-
pression exerted on the vein caused a dramatic ipsilateral
spermatic varicocele. The pancreatic gland at the tail, the
splenic artery and vein as well as the left colonic flexure
were displaced anteriorly. Preoperatively, his routine
biochemistry was normal (hemochrome with formula,
liver and kidney function), while his serum cortisol level
was increased (cortisol at 10 a.m. = 743 nmol/L, cortisol
at 2 p.m. = 637 nmol/L, cortisol at 6 p.m. = 649 nmol/L;
ranges, 7 a.m. to 10 a.m., 171 to 536 nmol/L; 4 to 8 p.m.,
64 to 327 nmol/L). His glucose level was 122 mg/dL
(range, 60 to 110 mg/dL). His urinary catecholamines
were normal.
A surgical left adrenalectomy was performed. The
surgically removed myelolipoma showed it to have an
oval shape (about 25 cm × 20 cm × 20 cm), and it
weighed 4.4 kg. Sectioning revealed areas representing
well-differentiated fat. The histological examination
revealed the presence of adipose tissue with hemato-
poietic elements without signs of cellular atypia, thus
confirming the initial diagnosis. The patient’s post-
operative course was altogether uneventful.
Discussion
Adrenal myelolipoma is often an “incidentaloma,” since its
diagnosis is frequently based on autopsic findings or upon
diagnostic imaging examinations performed for reasons
unrelated to its presence. These tumors are rare, although
they are increasingly being detected because of wider use
of diagnostic imaging techniques. They are benign and
nonfunctional tumors composed of mature adipocytes and
active hematopoietic elements. Their histogenesis is uncer-
tain. According to some authors, the tumor develops from
Figure 1 US scan of the abdomen showing a myelolipoma. A homogeneous hyperechoic mass in the upper abdomen that displaces the
left kidney downward is shown.
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residual embryonic cells of the bone marrow that, after
embolization, reach the adrenal gland. According to a
recent theory, myelolipoma originates from a metaplastic
process of the reticuloendothelial cells within adrenal
capillaries. Some authors even consider the development
of adrenal myelolipomas as a response to various endo-
crine stimulations [2]. This hypothesis is confirmed by the
autopsic findings of myelolipomas in patients who died as
a result of chronic systemic diseases. Other contemporary
authors have speculated about a stressful lifestyle and an
unbalanced diet as factors that may be involved in the
pathogenesis of this tumor [4]. An increase in mass is very
slow, becoming symptomatic only when, because of an
increase in the volume of tumor compression, phenomena
are diagnosed and/or the tumor spreads to neighboring
organs. Hemorrhage or necrosis that occur within the
tumor can cause pain. Hypertension and hematuria may
be other symptoms reported by the patient, who usually
has a strong constitution or may be obese [2]. Myelolipo-
mas associated with Cushing’s syndrome, Conn syndrome
and congenital adrenal hyperplasia caused by a deficiency
of 21-a hydroxylase or 17-a hydroxylase [3,10] have been
described. An unusual and unexplained observation is the
predominance of the tumor borne by the right adrenal
gland [4]. The differential diagnosis should include renal
angiomyolipoma, retroperitoneal lipoma and liposarcoma
[12].
In the clinical case we have described here, it is interest-
ing to note the hyperincretion of cortisol by the myeloli-
poma. This hyperincretion was probably responsible for
the patient’s hypertension, since his blood pressure was
normalized after surgical removal of the tumor and there-
after his blood pressure remained within normal values.
Another rare feature to consider is the left-sided posi-
tion of the myelolipoma in our patient, because they
have been reported in the literature to be prevalent
mostly on the right side. This location has probably
facilitated the rise of a left spermatic varicocele even if
the patient is asymptomatic.
Conclusions
The “incidental” discovery of an adrenal mass requires
careful diagnostic study to plan an appropriate treat-
ment. Imaging techniques at our disposal today can help
the clinician to render the diagnosis. Since myelolipo-
mas consist mainly of adipose tissue, their sharp hypere-
chogenicity observed on US may orient the clinician
toward the diagnosis, but US does not yield any certain
detail about nature of lipomatous lesions. CT can clarify
the nature of incidentalomas, as in our patient, and can
indicate the best treatment, taking into consideration
the tumor size and its possible hormone production.
Biochemical studies are also useful and necessary in the
typing of the mass.
Figure 2 Myelolipoma identified by CT. Contrast-enhanced CT scan of the upper abdomen shows a large heterogeneous mass covering the
upper left retroperitoneal space.
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Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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